Mentorship in research on opioid use disorder, HIV and marginalized populations

类阿片使用障碍、艾滋病毒和边缘化人群研究方面的导师 注射毒品（PWID）的人有过量服用的高风险，并增加了艾滋病毒的风险，但他们的次优 接受基于证据的阿片类药物使用障碍（OUD）治疗和艾滋病毒预防措施。接合PWID 和来自边缘化群体的OUD患者需要创新的方法。亚伦·D福克斯，MD MS是一个 成瘾医学医生和阿尔伯特·爱因斯坦医学院医学副教授- 蒙特菲奥里医疗中心他是一位经验丰富的研究导师，布朗克斯过渡诊所的主任， 它为以前被监禁的人提供了一个医疗之家， 创新的丁丙诺啡治疗干预措施的临床试验（见下文）。爱因斯坦-蒙蒂菲奥里研究所 临床和转化研究，以及爱因斯坦-洛克菲勒-纽约市立大学艾滋病研究中心，提供了一个 为支持早期研究人员和受训人员提供出色的环境。作为NIH治疗的一部分， 作为一项倡议，Einstein-Montefiore最近获得了IMPOWR的四笔赠款之一，用于建立一个研究中心 慢性疼痛和口腔溃疡在这个K24职业生涯中期导师奖，福克斯博士建议利用这些 资源，指导六个有才华的早期研究人员在研究OUD，艾滋病毒和边缘化 人口。福克斯博士还将获得指导技能，新的研究方法和药物政策的领导 具有以下职业发展目标：1）为不同的早期阶段提供出色的指导 研究人员将在OUD治疗和HIV预防方面发展独立的研究事业; 2）获得 在互联网为媒介的艾滋病预防研究的技能;和3）将证据转化为临床指南， 关于获得戒毒治疗和艾滋病毒预防服务的政策。为了实现这些目标，福克斯博士 将召集一个咨询小组，在指导，互联网介导的研究和药物政策方面拥有专业知识， 参加专门针对研究指导和卫生政策领导的培训。福克斯博士目前的研究 提供一个独特的环境，使早期研究人员可以参与以患者为导向的研究， 初级保健、医院、注射器服务项目和监禁后的“过渡诊所”。福克斯博士负责 两项大型随机对照试验：丁丙诺啡微剂量诱导治疗 慢性疼痛（RM 1DA 055437），以及丁丙诺啡的有效性、安全性和成本效益 在注射器服务项目中开始治疗（R 01 DA 044878）。该应用程序还提出了新的互联网- 与第一个正式的基于互联网的邮件NEXT Distro合作， 注射器服务计划在美国。这些研究将作为学员的平台， 在以患者为导向的研究中发展职业生涯，这与药物政策和临床指南高度相关。 完成拟议的K24奖将推动OUD治疗和艾滋病毒预防的研究， 还扩大和多样化致力于OUD，艾滋病毒和边缘化人群的研究队伍。

Mentorship in research on opioid use disorder, HIV and marginalized populations People who inject drugs (PWID) are at high risk for overdose and increasing HIV risk, yet they sub-optimally receive evidence-based opioid use disorder (OUD) treatment and HIV prevention measures. Engaging PWID and persons with OUD from marginalized groups requires innovative approaches. Aaron D. Fox, MD MS is an Addiction Medicine physician and Associate Professor of Medicine at Albert Einstein College of Medicine- Montefiore Medical Center. He is an experienced research mentor, the director of the Bronx Transitions Clinic, which provides a medical home to formerly incarcerated individuals, and the principal investigator of two clinical trials of innovative buprenorphine treatment interventions (see below). Einstein-Montefiore’s Institute for Clinical and Translational Research, and the Einstein-Rockefeller-CUNY Center for AIDS Research, provide an outstanding environment for supporting early-stage investigators and trainees. As part of the NIH HEAL initiative, Einstein-Montefiore was recently awarded one of four IMPOWR grants to develop a research center on chronic pain and OUD. In this K24 mid-career mentorship award, Dr. Fox proposes to capitalize upon these resources in mentoring six talented early-stage investigators in research on OUD, HIV, and marginalized populations. Dr. Fox would also gain skills in mentoring, new research methods, and drug policy leadership with the following career development objectives: 1) To provide outstanding mentorship to diverse early-stage investigators who will develop independent research careers in OUD treatment and HIV prevention; 2) To gain skills in internet-mediated HIV prevention research; and 3) To translate evidence into clinical guidelines and policy regarding access to addiction treatment and HIV prevention services. To meet these objectives, Dr. Fox will convene an advisory team with expertise in mentoring, internet-mediated research, and drug policy, while participating in training specific to research mentoring and health policy leadership. Dr. Fox’s current studies provide a unique environment where early-stage investigators can participate in patient-oriented research in primary care, hospitals, syringe services programs, and a post-incarceration “transitions clinic.” Dr. Fox leads two large randomized controlled trials: buprenorphine microdose inductions for hospitalized patients with chronic pain (RM1DA055437), and the effectiveness, safety, and cost-effectiveness of buprenorphine treatment initiation at syringe services programs (R01DA044878). This application also proposes new internet- mediated HIV prevention research in collaboration with NEXT Distro, the first formal internet-based mail delivery syringe services program in the United States. These studies will serve as a platform for trainees to develop careers in patient-oriented research that is highly relevant for drug policy and clinical guidelines. Completion of the proposed K24 award would advance research in OUD treatment and HIV prevention, while also expanding and diversifying the research workforce dedicated to OUD, HIV, and marginalized populations.